Navigation Links
Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Date:7/24/2008

ns and symptoms of acute agitation. In March 2007, Alexza announced positive initial results from a multi-center, randomized, double-blind, placebo-controlled Phase 2 clinical trial in 129 patients in an in-patient clinical setting. The 10 mg dose of AZ-004 met the primary endpoint of the clinical trial, which was a statistically significant reduction in the measure of agitation from baseline to the 2-hour post-dose time point, as compared to placebo. The 10 mg dose of AZ-004 also exhibited a rapid onset of effect, with a statistically significant improvement in the PEC scores at 20 minutes post-dose, as compared to placebo. The effectiveness of the AZ-004 10 mg dose was sustained throughout the 24-hour study period, as compared to placebo.

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing and completed the enrollment of its first Phase 3 clinical trial in June 2008. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
2. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
3. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
4. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
5. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
6. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
7. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
8. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
9. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
10. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
11. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... DIEGO , Oct. 22, 2014 AVACEN ... medical device received 510 (k) OTC clearance by the ... AVACEN 100 to be marketed over the Internet for: ... arthritis; muscle spasms; and minor strains and sprains . ... The AVACEN 100 (MSRP $2495) is a sophisticated ...
(Date:10/22/2014)...   BioNano Genomics , the genome mapping ... to purchase an Irys™ System . Among them ... (NCI), NIH Intramural Sequencing Center (NISC) and Genoscope (The ... comprehensive view of a genome was a major ... deliver the scalability or reliability to detect and ...
(Date:10/22/2014)... 22, 2014 InVivo Therapeutics Holdings Corp. (OTCQB: ... is revolutionizing spinal cord injury (SCI) treatment with their ... outperform in tissue regrowth in the spinal cord area ... an FDA approved polymer, the scaffold ultimately breaks down ... the human body. NVIV has recently attracted significant investor ...
Breaking Medicine Technology:AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3
... /PRNewswire-FirstCall/ - Pacgen,Biopharmaceuticals Corporation ("Pacgen") is pleased to ... of PAC-113, a novel,antifungal, show it is generally ... Candida infection with clinical cure rates,comparable to the ... Company plans to initiate a Phase IIb study ...
... Large multi-year, multi-hospital retrospective database analysis,demonstrates RDS ... significantly improved neonatal,survival --, NAPA, Calif. and ... Data,presented today at the Pediatric Academic Societies' ... Respiratory,Distress Syndrome (RDS) have a nearly 20% ...
Cached Medicine Technology:Pacgen Announces Positive Results from Phase I/II Trial of Novel,Antifungal Drug 2Pacgen Announces Positive Results from Phase I/II Trial of Novel,Antifungal Drug 3Pacgen Announces Positive Results from Phase I/II Trial of Novel,Antifungal Drug 4Pacgen Announces Positive Results from Phase I/II Trial of Novel,Antifungal Drug 5Preterm Infants with Respiratory Distress Syndrome: Incidence Rates,of Death when Treated with Surfactant Replacement Therapies 2Preterm Infants with Respiratory Distress Syndrome: Incidence Rates,of Death when Treated with Surfactant Replacement Therapies 3Preterm Infants with Respiratory Distress Syndrome: Incidence Rates,of Death when Treated with Surfactant Replacement Therapies 4Preterm Infants with Respiratory Distress Syndrome: Incidence Rates,of Death when Treated with Surfactant Replacement Therapies 5
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, ... vitro fertilization (IVF) -- the incubation of embryos in a ... inside the vagina, new research suggests. Scientists from the ... INVOcell, might sharply cut costs for pricey IVF procedures among ... to those who don,t live near big-city assisted reproduction centers, ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... health officials on Monday officially tightened guidelines for health workers ... skin exposure and use of a respirator at all times. ... to issue the tougher rules after two Dallas nurses contracted ... the United States, Liberian national Thomas Eric Duncan. Nina Pham ...
(Date:10/20/2014)... Dallas, Texas (PRWEB) October 20, 2014 ... is the must-have source of thousands of facts, figures ... 72 countries and 68 medical sector forecast categories the ... you with global, regional and national views on the ... future outlook. , The report gives you data for ...
(Date:10/20/2014)... PA (PRWEB) October 20, 2014 Allegheny ... minimally-invasive procedure that enables physicians to repair a damaged ... The MitraClip system, developed by Abbott ... (MR), a progressive and life-threatening condition in which the ... blood to flow backward from the heart’s left ventricle ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 ASCNYC ... organization that helps New Yorkers living with HIV/AIDS ... toward health, housing, recovery and self-sufficiency. Each year, ... the local community through their tireless efforts. , ... Marc Shapses , has been selected as this ...
Breaking Medicine News(10 mins):Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
... of suicide according to an Ottawa doctor. ,The research ... showed the results of the analysis // of 1.3 million ... which revealed that 19 out of every 1,000 male cancer ... committed suicide. ,The rate of suicides was found to ...
... unravel all possible factors that could probably play a ... baffled doctors worldwide for years together, // has homed ... reason for triggering off the development of autism in ... adversely affects the communication skills and social interactions of ...
... Stapling of hemorrhoids — a relatively new and ... higher risk of recurrence and prolapse than conventional ... comprehensive review of clinical studies. ,In contrast ... not remove hemorrhoids but treats them by inhibiting ...
... demonstrated how intense struggle among the human immune system's T ... and take on a more virulent form, developing into the ... computer model of simultaneous virus and immune system evolution, also ... against the virus. The research, which is slated for ...
... most resistant leukemia can be treated with a superior ... fails, as showed by the clinicians at the St. ... Jude technique allows blood stem cells to come from ... aggressive, toxic treatments that usually must accompany the transplant. ...
... implant makers on Friday said that Canadian regulators have given ... back on the market. // ,Allergan Inc., popular for ... the company a license for sale of both its round, ... Shaped and Textured implants. Earlier this year Allergan entered the ...
Cached Medicine News:Health News:Risk of Suicide in Cancer Patients 2Health News:Hemorrhoid Stapling Has More Long-Term Risks Than Surgical Removal 2Health News:Hemorrhoid Stapling Has More Long-Term Risks Than Surgical Removal 3Health News:HIV Takes Advantage of Rivalry among T cells 2Health News:HIV Takes Advantage of Rivalry among T cells 3Health News:Partial-match cell transplants for kids with resistant leukemia 2Health News:Partial-match cell transplants for kids with resistant leukemia 3
... PLUS pachometers are acknowledged to be the ... pachometers available. These benefits are due to ... and smallest tip footprint available coupled with ... for every displayed reading. Thus corneal thickness ...
... versatile and uncomplicated use of the Leica ... obtained make it the instrument of choice ... cryostat applications. The open top stainless steel ... accessible and offers ample space for convenient ...
... the new style of Bright cryostat. ... OTF/AS cryostat, the new OTF5000 incorporates ... ever-reliable and powerful 5040 microtome. A ... package deals makes the range of ...
... The Leica TP1020 product family are ... a perfect combination of approved technology with ... processing and maximum safety for tissues at ... engineering design based on proven precision mechanics ...
Medicine Products: